In Palo Alto, California, Medable Inc. revealed a significant development in agentic clinical development. A recent analysis conducted by Tufts Center for the Study of Drug Development (CSDD) demonstrated that utilizing an AI clinical monitoring agent could yield substantial financial benefits. The study indicated that such an agent has the potential to generate net financial gains of up to $21 million per drug development program, translating to an impressive 82 times return on investment. These conclusions were drawn from assessed oncology program and clinical trial data provided by Tufts CSDD, in addition to contract value and industry experience.
